AU714209B2 - Method of cancer treatment by p53 protein control - Google Patents

Method of cancer treatment by p53 protein control Download PDF

Info

Publication number
AU714209B2
AU714209B2 AU26206/95A AU2620695A AU714209B2 AU 714209 B2 AU714209 B2 AU 714209B2 AU 26206/95 A AU26206/95 A AU 26206/95A AU 2620695 A AU2620695 A AU 2620695A AU 714209 B2 AU714209 B2 AU 714209B2
Authority
AU
Australia
Prior art keywords
protein
nucleic acid
lys
calpain
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU26206/95A
Other languages
English (en)
Other versions
AU2620695A (en
Inventor
Jean-Marie Blanchard
Serge Carillo
Marc Peichaczyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Publication of AU2620695A publication Critical patent/AU2620695A/en
Application granted granted Critical
Publication of AU714209B2 publication Critical patent/AU714209B2/en
Assigned to AVENTIS PHARMA S.A. reassignment AVENTIS PHARMA S.A. Request to Amend Deed and Register Assignors: RHONE-POULENC RORER S.A.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU26206/95A 1994-05-31 1995-05-22 Method of cancer treatment by p53 protein control Ceased AU714209B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR94/06583 1994-05-31
FR9406583A FR2720277B1 (fr) 1994-05-31 1994-05-31 Méthode de traitement des cancers par régulation de la protéine P53.
PCT/FR1995/000670 WO1995033060A1 (fr) 1994-05-31 1995-05-22 Methode de traitement des cancers par regulation de la proteine p53

Publications (2)

Publication Number Publication Date
AU2620695A AU2620695A (en) 1995-12-21
AU714209B2 true AU714209B2 (en) 1999-12-23

Family

ID=9463670

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26206/95A Ceased AU714209B2 (en) 1994-05-31 1995-05-22 Method of cancer treatment by p53 protein control

Country Status (8)

Country Link
EP (1) EP0763121A1 (fr)
JP (1) JPH10500978A (fr)
AU (1) AU714209B2 (fr)
CA (1) CA2190293C (fr)
FI (1) FI120501B (fr)
FR (1) FR2720277B1 (fr)
NO (1) NO321411B1 (fr)
WO (1) WO1995033060A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19518488C1 (de) * 1995-05-19 1996-10-10 Progen Biotechnik Gmbh Autoantigen, geeignet zur Feststellung einer Thromboseneigung
EP0799892A3 (fr) * 1996-04-05 1998-08-12 Takeda Chemical Industries, Ltd. Calpain, sa préparation et son utilisation
US6232454B1 (en) * 1998-02-27 2001-05-15 Incyte Genomics, Inc. Human proteinase molecules
JP2002530085A (ja) * 1998-11-18 2002-09-17 カンジ，インコーポレイテッド 後期導入遺伝子の発現を有するウイルスベクター
WO2001074381A2 (fr) * 2000-03-31 2001-10-11 Parker Hughes Institute Inhibiteurs de calpaines pour le traitement du cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0159678A1 (fr) * 1984-04-20 1985-10-30 The Cancer Institute Of Japanese Foundation For Cancer Research Usage de 5-[(3,4-dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile
WO1993002106A1 (fr) * 1991-07-25 1993-02-04 The Mclean Hospital Corporation Inhibiteurs neuronaux de l'activite de proteinase neutre activee par le calcium

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0395309B1 (fr) * 1989-04-28 1995-12-27 Takara Shuzo Co. Ltd. Polypeptide semblable à la calpastatine humaine
JPH0641067A (ja) * 1992-04-20 1994-02-15 Kitasato Inst:The 新規カルパイン阻害物質ｋｐ−１２４１及びその製造法
EP0580161A1 (fr) * 1992-07-22 1994-01-26 THE McLEAN HOSPITAL CORPORATION Traitement prophylactique et thérapeutique de la maladie d'Alzheimer
US5607831A (en) * 1993-03-25 1997-03-04 The United States Of America As Represented By The Department Of Health And Human Services In vitro methods for assessing the susceptibility of HIV-1-infected individuals to cysteine protease-mediated activation-induced programmed cell death

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0159678A1 (fr) * 1984-04-20 1985-10-30 The Cancer Institute Of Japanese Foundation For Cancer Research Usage de 5-[(3,4-dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile
US4788219A (en) * 1984-04-20 1988-11-29 Cancer Institute, Japanese Foundation For Cancer Research Antimetastatic agent
WO1993002106A1 (fr) * 1991-07-25 1993-02-04 The Mclean Hospital Corporation Inhibiteurs neuronaux de l'activite de proteinase neutre activee par le calcium

Also Published As

Publication number Publication date
WO1995033060A1 (fr) 1995-12-07
CA2190293C (fr) 2011-06-28
FI964783L (fi) 1996-11-29
NO964772L (no) 1996-11-11
JPH10500978A (ja) 1998-01-27
AU2620695A (en) 1995-12-21
FR2720277A1 (fr) 1995-12-01
NO321411B1 (no) 2006-05-08
FI120501B (fi) 2009-11-13
FR2720277B1 (fr) 1996-07-12
FI964783A0 (fi) 1996-11-29
EP0763121A1 (fr) 1997-03-19
CA2190293A1 (fr) 1995-12-07
NO964772D0 (no) 1996-11-11

Similar Documents

Publication Publication Date Title
CA2174556C (fr) Procedes et compositions relatifs a l'adenovirus p53 recombine
CA2163256C (fr) Vecteurs adenoviraux d'origine animale et utilisation en therapie genique
CA2836987A1 (fr) Adenovirus chimeres a utiliser dans le traitement du cancer
AU724324B2 (en) p16 expression constructs and their application in cancer therapy
AU714209B2 (en) Method of cancer treatment by p53 protein control
EP0719328B1 (fr) Gene grb3-3, ses variants et leurs utilisations
US20070173443A1 (en) C-Terminal P53 Palindromic Peptide That Induces Apoptosis Of Cells With Aberrant P53 And Uses Thereof
US20010014319A1 (en) Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy
KR102566745B1 (ko) 암의 예방 또는 치료를 위한 Runx3 변이 단백질
AU730324B2 (en) Use of protein gax for treating cancer
WO1999055831A2 (fr) Vecteurs adenoviraux destines au traitement de maladies
KR101756131B1 (ko) 간세포 성장인자 및 기질세포 유발인자1알파를 이용한 말초동맥질환의 예방 또는 치료용 조성물
US7837991B2 (en) Method of cancer treatment by p53 protein control
MXPA96005522A (en) Method for the treatment of cancer through the control of protein
US7273854B1 (en) Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative disorders
WO2022186282A1 (fr) Thérapie génique hb-egf pour le diabète
FR2771423A1 (fr) Vecteurs permettant d'inhiber ou retarder la liaison d'un virus d'immunodeficience et/ou sa penetration dans une cellule cible
Bernloehr et al. Efficient propagation of single gene deleted recombinant Sendai virus vectors
FR2734826A1 (fr) Deltap62, ses variants, sequences nucleiques et leurs utilisations
Connelly Adenoviral vectors
EP0734447A1 (fr) Modele animal de la maladie d'alzheimer, preparation et utilisations
WO2003062373A2 (fr) Methodes et materiels de recrutement de cellules endotheliales
JP2006524712A (ja) カテプシンの阻害のための方法および組成物
US8431119B2 (en) Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
JP2007169223A (ja) アポトーシス促進剤およびそれを用いた医薬製剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)